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Abstract
Mutations within the BRCA1 tumor suppressor gene occur frequently in familial epithelial ovarian
carcinomas but they are a rare event in the much more prevalent sporadic form of the disease.
However, decreased BRCA1 expression occurs frequently in sporadic tumors, and the magnitude
of this decrease has been correlated with increased disease progression. The near absence of
somatic mutations consequently suggests that there are alternative mechanisms that may
contribute to the observed loss of BRCA1 in sporadic tumors. Indeed, both allelic loss at the
BRCA1 locus and epigenetic hypermethylation of the BRCA1 promoter play an important role in
BRCA1 down-regulation; yet these mechanisms alone or in combination do not always account for
the reduced BRCA1 expression. Alternatively, misregulation of specific upstream factors that
control BRCA1 transcription may be a crucial means by which BRCA1 is lost. Therefore,
determining how regulators of BRCA1 expression may be co-opted during sporadic ovarian
tumorigenesis will lead to a better understanding of ovarian cancer etiology and it may help foster
the future development of novel therapeutic strategies aimed at halting ovarian tumor progression.
Introduction
Epithelial ovarian cancer is the most lethal of all gyneco-
logical malignancies [1]. The poor survival associated
with ovarian carcinoma is due, at least in part, to the fact
that the disease is usually asymptomatic in its early stages.
As a result, detection often occurs at a late, metastatic stage
when the prognosis is poor. While the etiology of ovarian
carcinogenesis is poorly understood, evidence from his-
topathological studies and recently developed mouse
models of ovarian cancer progression suggest that the
majority of the tumors originate from the ovarian surface
epithelium (OSE), a simple cuboidal layer that covers the
surface of the ovary [2–5]. It remains unclear at this time,
however, if a predictable progression of molecular events
within the OSE gives rise to a well-defined neoplastic pre-
cursor that can be used to improve early detection and
diagnosis. Changes in a number of genes, including p53,
k-Ras, HER2/neu and c-Myc, have been implicated in
ovarian carcinoma progression. However, none of these
changes appear to occur in a stage-specific manner [6,7].
While global gene profiling approaches have recently
identified a number of genes that are differentially
expressed in epithelial ovarian cancer these alterations
have not yet been be fully characterized with respect to
stage, grade or functional importance [8–10]. Thus, to
date, the most compelling target gene linked to the devel-
opment of ovarian cancer continues to be the breast and
ovarian cancer susceptibility gene 1 (BRCA1).
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The protein products of the BRCA1 gene regulate, at least
in part, transcriptional activation, DNA repair, cell-cycle
checkpoint control, and chromosomal re-modeling [11].
Such multi-faceted contributions to essential cellular
functions imply a truly fundamental role for BRCA1 in
normal development but they also confound our under-
standing of its role in tumorigenesis [12]. This confusion
was initially compounded by the finding that complete
BRCA1 ablation in transgenic mice blocks embryonic pro-
liferation [13,14]. However, the subsequent generation of
a targeted knockout in the mouse mammary epithelium
did result in tumor formation, which is direct experimen-
tal evidence that BRCA1 can act as a tumor suppressor in
a susceptible tissue [15]. While a BRCA1 knockout has not
yet been targeted to the OSE there is compelling clinical
evidence that the gene is also a tumor suppressor in the
ovary. Drawing on parallels with the situation in the
breast, this review will focus on the possible means by
which a non-mutational suppression of BRCA1 can be
achieved in highly prevalent, non-familial, sporadic epi-
thelial ovarian carcinoma.
BRCA1 in familial and sporadic tumors
BRCA1 was originally isolated using positional cloning
techniques and inactivating mutations were found in fam-
ilies with a high incidence of breast and ovarian cancer
[16]. Specifically, germline alterations in the BRCA1 gene
result in a predisposed likelihood of developing early-
onset breast and ovarian cancer with a dominant pene-
trance as high as 85% and 65% respectively [17]. Tumor-
igenicity only occurs in these familial BRCA1
heterozygotes if there is also a loss of the second wild type
BRCA1 allele. The latter observation supports the notion
that the original germline BRCA1 mutation acts reces-
sively at the cellular level [18–20]. Although the presence
of an inherited mutation in one BRCA1 allele continues to
be one of the best-defined overall risk factors for the
development of breast or ovarian cancer, these familial
mutations, together with familial BRCA2 mutations,
occur in less than 10% of all diagnosed cases [21,22]. The
great majority of breast and ovarian carcinomas arise spo-
radically where inherited BRCA1 mutations do not occur.
In addition, somatic BRCA1 mutations are virtually unde-
tectable in sporadic breast cancers and they are extremely
rare in sporadic ovarian cancers [19,23–26]. Thus, at first
glance, it would not be unreasonable to conclude that
BRCA1 does not play a significant role in sporadic tumor
development. However, mounting evidence suggests that
alternative, non-mutational, mechanisms may suppress
BRCA1 expression in these tumors [27].
The first group to conclude that BRCA1 may be important
in sporadic tumor development observed a significant
decrease in BRCA1 mRNA in high grade, invasive breast
tumors [28]. The same investigators also demonstrated
that a suppression of BRCA1 activity has functional conse-
quences in cultured breast carcinoma cells [28]. Since
then, a number of studies have confirmed the association
between decreased BRCA1 mRNA and sporadic tumori-
genesis in both the breast and the ovary [29–31]. Further-
more, immunohistochemical analyses of BRCA1
expression in sporadic breast and ovarian cancers revealed
a significant reduction in BRCA1 protein [32,33]. This
suppression of BRCA1 expression appears to be achieved
through multiple means. For example, loss of heterozy-
gosity (LOH) at the BRCA1 locus occurs in a significant
proportion of sporadic of ovarian tumors [19,34]. Addi-
tionally, a comprehensive study by Russell et al. [35]
found that 44% of the tumors had BRCA1 allelic loss, yet,
strikingly, this event did not account for the loss of BRCA1
protein expression. Finally, 18% of the tumors exhibited
a complete loss of BRCA1 protein in the absence of both
LOH and allelic loss [35]. Taken together, these data indi-
cate that epigenetic misregulation also contributes to the
reduction of BRCA1 expression in sporadic tumors.
Epigenetic regulation of BRCA1
Hypermethylation of the BRCA1 promoter
Promoter hypermethylation is used during normal devel-
opment to epigenetically downregulate gene expression in
a tissue-specific manner. Methylation of the DNA occurs
most frequently on the 5' cytosine residues within 5'-CpG-
3' di-nucleotides, which often cluster together in CpG
islands that can stretch for several kilobases [36]. In
actively transcribed genes, CpG islands within regulatory
regions are often unmethylated. In contrast, methylation
at these sites represses transcription by altering chromatin
structure such that the transcriptional machinery does not
have proper access to functionally important regions of
the promoter [37]. The proximal BRCA1 promoter lies
within such a methylation-sensitive island and a develop-
mentally inappropriate hypermethylation of the pro-
moter does occur in some sporadic breast and ovarian
tumors [38,39]. This hypermethylation may be function-
ally significant as it correlates with decreased BRCA1
mRNA [40]. An important question, yet to be answered, is
whether such an abnormal promoter hypermethylation is
the cause or consequence of an initial transcriptional
repression [41]. Regardless, promoter hypermethylation
has only been found in tumors where BRCA1 LOH has
also occurred [40]. Thus, hypermethylation may serve as
an epigenetic 'second hit' that inactivates the remaining
wild type BRCA1 allele after LOH has occurred. While
inappropriate promoter hypermethylation is very likely a
powerful repressor of BRCA1 expression it is important to
point out that it only occurs in a small subset of sporadic
tumors [42,43].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/72
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Transcriptional regulation of BRCA1
The primary proximal BRCA1 promoter, which consists of
less than 300 base pairs (bp), lies immediately upstream
of the major breast-specific transcription start site located
within the gene's first exon [44,45]. The regulation of this
promoter is complex and a number of candidate regula-
tory sites have been identified and partially characterized
(Fig 1). One of these elements, the positive regulatory
region (PRR) at the 5' end of the promoter is both neces-
sary and sufficient to maximally activate BRCA1 transcrip-
tion [46]. Of particular interest, one putative regulatory
site located within the PRR is a cyclic-AMP response ele-
ment, which is capable of specifically binding to CREB,
the cyclic-AMP response element binding protein [47].
Importantly, this element is a site of frequent hypermeth-
ylation in breast and ovarian tumors [48] and experimen-
tal methylation of this site decreases BRCA1 promoter
activity in vitro [49]. Mutation of the CREB-binding con-
sensus sequence within the context of an intact BRCA1
promoter [49] also causes a significant reduction in pro-
moter activation in non-tumorigenic human OSE cells in
culture [50]. Taken together, these findings indicate that
the cAMP-response element is very likely an important
positive regulator of BRCA1 expression in both the nor-
mal OSE and in tumor tissue. As an initial transcriptional
repression is capable of contributing to the later hyper-
methylation of sensitive sites [41] misregulation of the
transcriptional complex that binds to the cAMP-response
element in the BRCA1 promoter could contribute to spo-
radic ovarian carcinoma development. Therefore, a care-
ful examination of the signal transduction pathways that
influence the activity and/or binding of transcriptional
complexes to the cAMP-response element in the BRCA1
promoter may identify potentially important oncogenic
events in sporadic ovarian carcinoma development.
Schematic of the proximal BRCA1 promoter and the 8 functional sites that have been well characterized in breast cells Figure 1
Schematic of the proximal BRCA1 promoter and the 8 functional sites that have been well characterized in breast cells. The 
RIBS and CREB sites have recently been partially characterized in ovarian surface epithelial and in ovarian carcinoma cells (see 
text for details).
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It is conceivable that a number of the other transcriptional
regulators of the BRCA1 promoter may also play a role in
sporadic ovarian and breast carcinogenesis [27]. One such
example is the GA-binding protein α/β (GABPα/β) which
is a member of the ETS family of transcription factors [51].
GABPα/β specifically binds to three consecutive ETS fac-
tor-binding domains (described as the RIBS element)
located immediately upstream of the CRE element in the
positive response region (Fig 1) [52]. Transient overex-
pression of GABPα/β in breast carcinoma cells is able to
stimulate BRCA1 promoter transactivation, thus demon-
strating that it is potentially a direct positive regulator of
BRCA1 expression [52]. Thus, loss of GABPα/β or lost
responsiveness to GABPα/β-containing transcription fac-
tor complexes could result in decreased BRCA1 expression
in sporadic tumors. Indeed, the promoter binding ability
and transcriptional induction by GABPα/β is significantly
reduced in mammary carcinoma cells. Comparatively, in
the ovary the GABPα/β-binding RIBS element is highly
active in normal OSE cells but not in ovarian carcinoma
cells [50]. This intriguing observation suggests that the
RIBS element, and perhaps aberrant function of the fac-
tors responsible for its regulation, may be specifically
important in the repression of BRCA1 in sporadic ovarian
tumors.
Other DNA-binding proteins that may act on the RIBS ele-
ment in the BRCA1 promoter are ID4 and ETS-2. ID4 is a
recognized repressor of BRCA1 expression in both breast
and ovarian carcinoma cell lines [53] that negatively reg-
ulates transcription by forming heterodimers with tran-
scription factors through their helix-loop-helix domain
[54]. ETS-2 is a member of the ETS family of transcription
factors related to GABPα/β that also directly binds to the
BRCA1 promoter in the RIBS domain [55]. Unlike
GABPα/β, ETS-2 overexpression represses BRCA1 tran-
scription which raises the possibility that multiple ETS
factors may compete for binding within the RIBS domain
such that upstream signaling pathways which differen-
tially modulate the activation of these transcriptional
complexes may be the critical regulators of BRCA1
expression.
Conclusion
Transcriptional suppression of the BRCA1 promoter
occurs in sporadic ovarian carcinoma. Clearly, hyper-
methylation of the promoter plays an important role in
this process. In addition, alterations in the transcription
factor complexes that bind to the promoter also have a
role to play, either upstream of hypermethylation or inde-
pendent of it. Therefore, the future identification of criti-
cal regulators of these complexes will point the way to
functionally important signaling pathways that are co-
opted during sporadic ovarian tumor formation and
progression.
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